VRNA Executive Compensation
* In USD (Original Currency)|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total |
|---|---|---|---|---|---|---|---|---|
| 2024-03-20 | 2023 | David Zaccardelli, Pharm.D. President and Chief Executive Officer (PEO) | 819,568 | 0 | 5,324,000 | 440,705 | 13,200 | 6,597,473 |
| 2024-03-20 | 2022 | Kathleen Rickard, M.D. Chief Medical Officer | 434,439 | 0 | 863,000 | 217,220 | 3,342 | 1,518,001 |
| 2024-03-20 | 2023 | Kathleen Rickard, M.D. Chief Medical Officer | 458,333 | 0 | 1,331,000 | 192,500 | 0 | 1,981,833 |
| 2024-03-20 | 2022 | Mark W. Hahn Chief Financial Officer | 430,450 | 0 | 3,983,498 | 331,531 | 22,401 | 4,767,880 |
| 2024-03-20 | 2023 | Mark W. Hahn Chief Financial Officer | 551,291 | 0 | 5,324,000 | 293,803 | 13,200 | 6,182,294 |
| 2024-03-20 | 2022 | David Zaccardelli, Pharm.D. President and Chief Executive Officer (PEO) | 524,842 | 0 | 4,133,500 | 497,297 | 27,501 | 5,183,140 |
| 2023-03-21 | 2022 | David Zaccardelli, Pharm.D. President and Chief Executive Officer (PEO) | 524,842 | 0 | 4,133,500 | 497,297 | 27,501 | 5,183,140 |
| 2023-03-21 | 2021 | David Zaccardelli, Pharm.D. President and Chief Executive Officer (PEO) | 272,500 | 0 | 496,035 | 328,313 | 26,456 | 1,123,304 |
| 2023-03-21 | 2022 | Mark W. Hahn Chief Financial Officer | 430,450 | 0 | 3,983,498 | 331,531 | 22,401 | 4,767,880 |
| 2023-03-21 | 2021 | Mark W. Hahn Chief Financial Officer | 402,500 | 0 | 99,210 | 218,875 | 17,704 | 738,289 |
| 2023-03-21 | 2022 | Kathleen Rickard, M.D. Chief Medical Officer | 434,439 | 0 | 863,000 | 217,220 | 3,342 | 1,518,001 |
| 2023-03-21 | 2021 | Kathleen Rickard, M.D. Chief Medical Officer | 413,751 | 0 | 0 | 140,675 | 7,957 | 562,383 |
| 2022-03-22 | 2020 | Kathleen Rickard Chief Medical Officer | 401,700 | 125,000 | 3,201,340 | 176,748 | 19,314 | 3,966,115 |
| 2022-03-22 | 2021 | David Zaccardelli President and Chief Executive Officer | 272,500 | 0 | 496,035 | 328,313 | 26,456 | 1,123,304 |
| 2022-03-22 | 2020 | David Zaccardelli President and Chief Executive Officer | 229,167 | 0 | 17,620,462 | 412,500 | 39,110 | 18,301,239 |
| 2022-03-22 | 2021 | Mark Hahn Chief Financial Officer | 402,500 | 0 | 99,210 | 218,875 | 17,704 | 738,289 |
| 2022-03-22 | 2020 | Mark Hahn Chief Financial Officer | 229,167 | 0 | 17,915,584 | 275,000 | 35,047 | 18,454,798 |
| 2022-03-22 | 2021 | Kathleen Rickard Chief Medical Officer | 413,751 | 0 | 0 | 140,675 | 7,957 | 562,383 |
| 2021-03-19 | 2020 | David Zaccardelli President and Chief Executive Officer | 229,167 | 0 | 17,620,462 | 412,500 | 39,110 | 18,301,239 |
| 2021-03-19 | 2019 | Jan-Anders Karlsson Former Chief Executive Officer | 437,828 | 0 | 199,607 | 231,173 | 30,315 | 1,539,700 |
| 2021-03-19 | 2020 | Jan-Anders Karlsson Former Chief Executive Officer | 82,662 | 0 | 0 | 0 | 1,392,124 | 1,474,786 |
| 2021-03-19 | 2019 | Kathleen Rickard Chief Medical Officer | 357,500 | 125,000 | 89,905 | 121,550 | 9,633 | 962,173 |
| 2021-03-19 | 2020 | Kathleen Rickard Chief Medical Officer | 401,700 | 125,000 | 3,201,340 | 176,748 | 19,314 | 3,966,115 |
| 2021-03-19 | 2020 | Mark Hahn Chief Financial Officer | 229,167 | 0 | 17,915,584 | 275,000 | 35,047 | 18,454,798 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
